Induction of ovulation and ovarian cancer: a critical review of the literature.

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, New York, USA.
Fertility and sterility (Impact Factor: 4.3). 05/2006; 85(4):819-26. DOI: 10.1016/j.fertnstert.2005.08.061
Source: PubMed

ABSTRACT To critically examine the possible association between ovulation-inducing drugs and ovarian cancer.
Medline literature review and cross-reference of published data.
The studies that have adjusted for the effects of confounding factors such as duration of oral contraceptive use and number of pregnancies have noted an increased risk of ovarian cancer among infertile women who remain childless despite long periods of unprotected intercourse. Whether such women are at risk due to the primary basis for their infertility or factors such as ovulation-inducing drugs, has been the subject of several studies. Overall, the findings on ovarian cancer (especially invasive epithelial and non-epithelial) risk associated with fertility drug treatment are reassuring. However, a stronger association between fertility drug use and borderline tumors of the ovary has been observed.
Despite the overall reassuring findings of the available studies, there is a need for well-designed clinical trials to understand the possible carcinogenic effects of the ovulation-inducing drugs.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers are vital to detect diseases in various clinical stages. A variety of cancer serum biomarkers are already known, while for more accurate cancer-type detection, there required more rigorous evaluation manners, especially computational evaluation measures, for biomarkers. In this review, we first show three typical pitfalls in finding biomarkers and their examples, after briefly presenting standard five clinical biomarker screening phases by National Cancer Institute. We then introduce current computational biomarker evaluation measures, including current, standard methods with their intrinsic features. We further show an up-to-date list of existing cancer serum biomarkers, pointing out several issues, being caused by the limitations of current biomarker evaluation approaches. Finally we discuss the current attempts to develop new, statistically robust, computational serum-based biomarker measures in terms of specificity to each of various cancer types.
    Critical Reviews in Oncology/Hematology 10/2014; · 4.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To study the clinical and histopathological presentation of ovarian masses. Method Retrospective analysis of 205 cases from May 2009 to June 2013. Results Incidence of ovarian masses was 6.9 %. Among 205 cases, 68 % were neoplastic. Among the neoplasms, 87.8 % were benign, 10 % malignant, and 2.2 % borderline. Mean ages of malignant and benign neoplasm were 41 and 39 years, respectively. 42.9 % malignant tumors presented with non-specific abdominal and constitutional symptoms. Serous cystadenoma was the commonest benign tumor (67 %) followed by Mucinous (19 %) and Dermoid (11.6 %). Most common malignant ovarian tumor was Serous cystadenocarcinoma (42.9 %). Out of the malignant cases, all were primary except one secondary deposit from Non-Hodgkin’s Lymphoma. Only 28.6 % presented at stage I, remaining presented at stage III/IV. Conclusion Ovarian neoplasms have twice the incidence of non-neoplasms. Mean age of malignant tumors is decreased. Rising trend in Mucinous cystadenoma is noted.
    Journal of Obstetrics and Gynecology of India 01/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Key contentIncreasing availability and expanding usage of infertility treatment is a concern with regard to a possible increase in the risk of future malignancy development for women and their offspring.Infertile women are at significantly increased risk of developing ovarian and uterine cancers, especially nulliparous women.Earlier studies pointed to a possible increase in the risk of ovarian cancer following large doses and multiple cycles of clomiphene citrate.Recent studies did not observe any increase in malignancy risk due to infertility medications. Other confounding factors, such as infertility itself, may well be the reason for the increased percentage of cancer cases noted in earlier studies.Uterine cancer risk is possibly increased following multiple cycles and high doses of clomiphene citrate.There is no strong evidence linking infertility treatment with non-gynaecological or childhood cancers, with the possible exception of melanoma. Learning objectivesTo highlight the available evidence linking infertility treatment with gynaecological, non-gynaecological and childhood cancers.How to counsel women about any possible risk of future neoplasia after infertility treatment. Ethical issuesIs it ethical to persevere with multiple fertility treatment cycles if it might be associated with increased risk of neoplasia in the future?
    The Obstetrician & Gynaecologist 07/2013; 15(3).

Full-text (2 Sources)

Available from
May 19, 2014